A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers

Current Medical Research and Opinion

Volumn 22, Issue 3, 2006, Pages 501-509

  Schmid Grendelmeier, Peter ^a   Pokorny, Rolf ^b   Gasser, Urs E ^c   Richarz, Ute ^d,e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Swiss Pharma Contract Ltd   (Switzerland)

^c ClinResearch GmbH   (Switzerland)

^d Janssen Cilag   (Switzerland)

^e Cilag AG   (Switzerland)

Author keywords

Buprenorphine; Erythema; Fentanyl; Transdermal delivery system

Indexed keywords

BUPRENORPHINE; FENTANYL; NALTREXONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PATCH TEST; SINGLE DRUG DOSE; SKIN EXAMINATION; SKIN IRRITATION; VOLUNTEER; VOMITING;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG DELIVERY SYSTEMS; ERYTHEMA; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SKIN; STATISTICS, NONPARAMETRIC;

EID: 33645218529     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X89829     Document Type: Article

References (19)

1. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001;61:2289-307
2. Le Loet X, Pavelka K, Richarz U. Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip, an open, multicentre study. BMC Musculoskelet Disord 2005;6:31
3. Pavelka K, Le Loet X, Bjorneboe O, Herrero-Beaumont G, Richarz U. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Curr Med Res Opin 2004;20:1967-77
4. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2(4):197-204
5. Muriel C, Failde I, Mico JA, Neira M, Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 2005;27:451-62
6. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26: 1808-20
7. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150-68
8. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419-28
9. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457-69
10. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322:1154-8
11. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life [The TTS-Fentanyl Comparative Trial Group]. J Pain Symptom Manage 1997;13:254-61
12. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64(3):527-34
13. Sathyan G, Guo C, Sivakumar K, Gidwani S, Gupta S. Bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005;21(12):1961-8
14. Summary of products characteristics. Durogesic®. Available at: http://www.janssen-cilag.ie/product/professionals.asp
15. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug product. US Department of Health and Human Services; Food and Drug Administration, Centre for Drug Evaluation and Research (CDER); December 1999
16. Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: the Chromameter®, the DermaSpectrometer® and the Mexameter®. Skin Res Technol 2000;6:230-8
17. Summary of products characteristics. Transtec®. Available at: http://emc.medicines.org.uk [last updated: 13 July 2005]
18. Callejo Melgosa AM, Martinez JC, Fuentes MJ, Martin C. Allergic contact dermatitis from buprenorphine. Allergy 2005;60:1217-8
19. Elliott JC, Picker MJ, Nelson CJ, Carrigan KA, Lysle DT. Sex differences in opioid-induced enhancement of contact hypersensitivity. J Invest Dermatol 2003;121:1053-9